Pulmonary Hypertension Technology Developer Pulnovo Medical Raises Over 100 Million Yuan in Funding
China's first cardiovascular company in the pulmonary hypertension space to receive FDA Breakthrough Device designation.
Pulnovo Medical recently announced the completion of a new funding round exceeding 100 million yuan, with Gaorong Ventures participating as an investor. The proceeds will be used primarily for full pipeline product deployment and the launch of global multi-center clinical trials.
Founded in 2013, Pulnovo Medical is dedicated to treating pulmonary hypertension using radiofrequency ablation technology. The company's two major product lines — high-frequency ablation equipment and intravascular catheters — are both world-first innovations, backed by multiple domestic and international invention patents.
Pulmonary hypertension (PH) is a pathophysiological syndrome characterized by elevated pulmonary artery pressure and pulmonary vascular resistance, caused by various underlying conditions. It ultimately leads to increased right ventricular load, right heart failure, and sudden death. Clinicians worldwide have never stopped researching PH treatments, but due to the unclear and complex pathogenesis, effective treatment remains a major challenge.
In early 2021, Pulnovo Medical's self-developed pulsed radiofrequency ablation catheter for treating pulmonary hypertension received FDA Breakthrough Device Designation. Previously, the company had completed full patient enrollment for its PADN-CFDA clinical trial and continued to assist participating centers with follow-up visits and subsequent work.
Pulnovo Medical noted that while clinical awareness of pulmonary hypertension has gradually increased, many physicians still lack familiarity with the disease. To address this, the company plans to gradually establish demonstration centers and education bases domestically after product approval, and intends to invite more top-tier tertiary hospitals to join. Internationally, numerous PH experts have expressed interest in participating in market education efforts to save more patients.
On the product front, Pulnovo Medical's radiofrequency ablation catheter delivers high-frequency electrical current from the ablation generator to designated electrodes, achieving therapeutic effects through sympathetic nerve ablation at target sites — a significant lead over competitors. As China's first cardiovascular company in the pulmonary hypertension space to receive FDA Breakthrough designation, Pulnovo Medical has previously explored all available energy platforms. Its current energy source represents an optimized solution that is stable and well-suited for PADN (Percutaneous Pulmonary Artery Denervation) procedures. Additionally, the self-developed catheter shape better conforms to pulmonary artery walls, enabling higher ablation efficiency, improved safety, and significantly reduced procedure times.
"As a completely new track with extremely high technical barriers, the path of global innovation is long and arduous. That's why we have consistently and carefully chosen professional healthcare investors as partners from the very beginning," said Cynthia Chen, Executive President of Pulnovo Medical. "We are grateful to our new and existing shareholders for their recognition and full support in helping Pulnovo expand its research and develop more products to benefit patients. With their assistance, we aim to use truly original Chinese innovation to address the deadly unmet needs in the pulmonary hypertension field."
Going forward, Pulnovo Medical will gradually roll out multi-center clinical trials globally to benefit more pulmonary hypertension patients.
Yang Kun, Partner at Gaorong Ventures, commented: "Pulmonary hypertension is known as the 'cancer of cardiovascular diseases.' Currently available treatment options are limited, patient prognosis is extremely poor, and there has long been enormous unmet clinical need. Pulnovo Medical is the global pioneer in pulmonary artery hypertension ablation procedures, and has been leading exploration and clinical practice in the PADN field worldwide for many years. The company's product has completed registration clinical enrollment in China, received FDA Breakthrough Device Designation in 2021 for Group 1, 2, and 4 pulmonary hypertension patients, and is about to begin U.S. clinical enrollment. Gaorong Ventures has always focused on investing in innovative medical products and technologies globally. We are pleased to walk alongside the company in jointly advancing PADN's commercialization worldwide, bringing hope to pulmonary hypertension patients."
Galixir Completes New Strategic Funding Round, Continues Advancing AI-Powered Drug R&D Pipeline
Innjia Biotech Completes Pre-A Round, Advancing High-End Protein Platform to New Level
